Home/Recalls/FDA-D-0251-2026
FDA DrugsClass II

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use In...

Published: January 14, 2026Recall ID: D-0251-2026Category: drugsCountry: US

Reason for Recall / Hazard

Presence of particulate matter - Glass like particles.

Product Description & Identification

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Affected Products

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Additional Source Details

FieldValue
CityLedgewood
StateNJ
Event id98181
Address 11705 Route 46 Ste 6B
Code infoLot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.
Postal code07852-9720
Report date20260114
Product typeDrugs
Product quantity314 boxes of 6,280 pre-filled syringes
Reason for recallPresence of particulate matter - Glass like particles.
Voluntary mandatedVoluntary: Firm initiated
Recall initiation date20251218
Initial firm notificationLetter
Center classification date20260102

Overview

  • Recalling FirmImprimis NJOF, LLC
  • StatusOngoing
  • Risk LevelClass II
  • DistributionU.S Nationwide
Official Agency Alert